$BOTH
BIOETHICS LTD

2024 Q3 Form 10-Q Financial Statement

#000147793224005085 Filed on August 19, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $22.98K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $39.28K $22.98K
YoY Change 292.68% 55.14%
Operating Profit -$39.28K -$22.98K
YoY Change 292.68% 55.14%
Interest Expense $13.80K $12.95K
YoY Change 12.22% 7.96%
% of Operating Profit
Other Income/Expense, Net -$13.80K -$12.95K
YoY Change 12.22% 7.96%
Pretax Income -$53.08K -$35.93K
YoY Change 138.04% 34.02%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$53.08K -$35.93K
YoY Change 138.04% 34.02%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.03
COMMON SHARES
Basic Shares Outstanding 1.135M shares 1.135M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.17K
YoY Change
Cash & Equivalents $17.15K $10.17K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $17.15K $10.17K
YoY Change 3451.35% 2049.68%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $17.15K $10.17K
Total Long-Term Assets $0.00 $0.00
Total Assets $17.15K $10.17K
YoY Change 3451.35% 2049.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $177.2K $150.7K
YoY Change 52.1% 34.92%
Accrued Expenses $108.9K
YoY Change 21.67%
Deferred Revenue
YoY Change
Short-Term Debt $491.7K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $880.1K $862.0K
YoY Change 16.98% 18.08%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $880.1K $862.0K
Total Long-Term Liabilities $0.00
Total Liabilities $880.1K $862.0K
YoY Change 16.98% 18.08%
SHAREHOLDERS EQUITY
Retained Earnings -$1.407M -$1.353M
YoY Change 12.21% 9.93%
Common Stock $1.135K $1.135K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$862.9K -$851.9K
YoY Change
Total Liabilities & Shareholders Equity $17.15K $10.17K
YoY Change 3451.35% 2049.68%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$53.08K -$35.93K
YoY Change 138.04% 34.02%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$33.02K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 43.10K
YoY Change
NET CHANGE
Cash From Operating Activities -33.02K
Cash From Investing Activities
Cash From Financing Activities 43.10K
Net Change In Cash 10.08K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$33.02K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000894560
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1135194 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1135194 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1135194 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
33-55254-41
dei Entity Registrant Name
EntityRegistrantName
BIOETHICS, LTD.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0485312
dei Entity Address Address Line1
EntityAddressAddressLine1
1661 Lakeview Circle
dei Entity Address City Or Town
EntityAddressCityOrTown
Ogden
dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
84403
dei City Area Code
CityAreaCode
801
dei Local Phone Number
LocalPhoneNumber
399-3632
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
true
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1135194 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10168 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
138 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
10168 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
138 usd
CY2024Q2 us-gaap Assets
Assets
10168 usd
CY2023Q4 us-gaap Assets
Assets
138 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
150679 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
122400 usd
CY2024Q2 both Accounts Payable Related Party
AccountsPayableRelatedParty
2500 usd
CY2023Q4 both Accounts Payable Related Party
AccountsPayableRelatedParty
14500 usd
CY2024Q2 both Accrued Interest Related Parties
AccruedInterestRelatedParties
108268 usd
CY2023Q4 both Accrued Interest Related Parties
AccruedInterestRelatedParties
98406 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
108887 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
98363 usd
CY2024Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
35000 usd
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
35000 usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
190000 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
160000 usd
CY2024Q2 both Notes Payable Related Parties
NotesPayableRelatedParties
266684 usd
CY2023Q4 both Notes Payable Related Parties
NotesPayableRelatedParties
247734 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
862018 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
776403 usd
CY2024Q2 us-gaap Liabilities
Liabilities
862018 usd
CY2023Q4 us-gaap Liabilities
Liabilities
776403 usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1135 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1135 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
500479 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
500479 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1353464 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1277879 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-851850 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-776265 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10168 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
138 usd
CY2024Q2 us-gaap Revenues
Revenues
0 usd
CY2023Q2 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22979 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14812 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50200 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26839 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
22979 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
14812 usd
us-gaap Operating Expenses
OperatingExpenses
50200 usd
us-gaap Operating Expenses
OperatingExpenses
26839 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22979 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14812 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-50200 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-26839 usd
CY2024Q2 us-gaap Interest Expense
InterestExpense
12953 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
11998 usd
us-gaap Interest Expense
InterestExpense
25385 usd
us-gaap Interest Expense
InterestExpense
23607 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12953 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11998 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-25385 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-23607 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35932 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26810 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-75585 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-50446 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-35932 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-26810 usd
us-gaap Net Income Loss
NetIncomeLoss
-75585 usd
us-gaap Net Income Loss
NetIncomeLoss
-50446 usd
CY2024Q2 both Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.03
CY2023Q2 both Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.02
both Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.07
both Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.04
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-776265 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-39653 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-815918 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-35932 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-851850 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-679116 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-23636 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-702752 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-26810 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-729562 usd
us-gaap Profit Loss
ProfitLoss
75585 usd
us-gaap Profit Loss
ProfitLoss
50446 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
28279 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
11417 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-12000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
3000 usd
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
9862 usd
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
13293 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
10524 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
10314 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38920 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12422 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
30000 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
18950 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
12600 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48950 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12600 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
10030 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
178 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
138 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
295 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10168 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
473 usd
us-gaap Interest Paid Net
InterestPaidNet
5000 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
both Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.07
both Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.04
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
15351 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
14694 shares
us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
1150545 shares
us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
1149888 shares

Files In Submission

Name View Source Status
0001477932-24-005085-index-headers.html Edgar Link pending
0001477932-24-005085-index.html Edgar Link pending
0001477932-24-005085.txt Edgar Link pending
0001477932-24-005085-xbrl.zip Edgar Link pending
biol_10q.htm Edgar Link pending
biol_ex311.htm Edgar Link pending
biol_ex321.htm Edgar Link pending
both-20240630.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
biol_10q_htm.xml Edgar Link completed
both-20240630_cal.xml Edgar Link unprocessable
both-20240630_def.xml Edgar Link unprocessable
both-20240630_lab.xml Edgar Link unprocessable
both-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable